Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT ID: NCT06251180
Last Updated: 2025-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
112 participants
INTERVENTIONAL
2024-04-10
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
NCT03876028
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
NCT01569750
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT05200312
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
NCT05189197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dose escalation portion(Part A): In the dose escalation portion of the study, the escalating doses of Rocbrutinib combined with R-CHOP may be explored, using the 3+3 principle for dose determination. If dose escalation is acceptable, and subsequently will determine the recommended Phase 2 dose.
Dose expansion portion(Part B): This will be conducted as a multicenter, open-label study, including three cohorts(Cohort 1: non-GCB DLBCL; Cohort 2: MZL; Cohort 3: MCL). Eligible subjects will receive Rocbrutinib combined with R-CHOP for 6 cycles, then Rocbrutinib plus Rituximab for 2 cycles, and followed by Rocbrutinib maintenance for 2 years.
After completion of study treatment, patients are followed up every 12 weeks for 1 year, then every 24 weeks for 4 year.
PRIMARY OBJECTIVES:
I. To evaluate the safety of Rocbrutinib in combination to R-CHOP in B-cell Non-Hodgkin Lymphoma, including the maximum tolerated dose (MTD), dose limiting toxicities(DLT), adverse events (AEs), clinically significant laboratory abnormalities.
2\. To determine the recommended dose. 3. To determine the pharmacokinetic characteristics of Rocbrutinib in combination to R-CHOP.
SECONDARY OBJECTIVES:
I. To determine the overall response rate, the complete response rate, duration of remission, survival outcomes (progression free survival, event free survival, overall survival) in DLBCL/ Non-germinal Center(non-GCB) DLBCL.
2\. To determine the overall response rate, the complete response rate, duration of remission, survival outcomes (progression free survival, event free survival, overall survival) in MZL.
3\. To determine the overall response rate, the complete response rate, duration of remission, survival outcomes (progression free survival, event free survival, overall survival) in MCL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP
Rocbrutinib
orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Rituximab
375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
Cyclophosphamide
750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
doxorubicin
50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Vincristin
1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Prednisone
100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Dose Expansion [non-GCB DLBCL]
Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP
Rocbrutinib
orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Rituximab
375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
Cyclophosphamide
750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
doxorubicin
50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Vincristin
1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Prednisone
100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Dose Expansion [MCL]
Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP
Rocbrutinib
orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Rituximab
375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
Cyclophosphamide
750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
doxorubicin
50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Vincristin
1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Prednisone
100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Dose Expansion [MZL]
Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP
Rocbrutinib
orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Rituximab
375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
Cyclophosphamide
750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
doxorubicin
50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Vincristin
1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Prednisone
100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rocbrutinib
orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Rituximab
375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
Cyclophosphamide
750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
doxorubicin
50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Vincristin
1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Prednisone
100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have at least one measurable lesion.
* ECOG physical status score 0-2.
* Life expectancy ≥6 months.
* International Prognostic Index (IPI) score ≥ 2 (only participants with DLBCL in dose expansion portion).
* Adequate coagulation, liver, kidney, and hematopoietic functions：PT and APTT \<1.5x ULN; serum bilirubin \<1.5x ULN except in participants with Gilbert's syndrome who must have a serum bilirubin of \<3x ULN, AST and ALT ≤ 3x ULN or \< 5x ULN if hepatic involvement are present; serum creatinine (Scr) ≤1.5 x ULN, or calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula.; ANC≥1500/mm3, hemoglobin≥8.0 g/dL, and platelets \>100,000/mm3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician.
* Women of childbearing potential must have a negative serum or urine (beta-human chorionic gonadotropin \[beta-hCG\]) at screening.
* Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective contraceptive measures of during and after the study (90 days after the last dose of ROCBRUTINIB and 12 months after the last dose of Rituximab). Men must agree to not donate sperm during and for up to 90 days after he last dose of ROCBRUTINIB.
* Participants voluntarily enrolled and signed the informed consent form, and followed the trial treatment and visits.
Exclusion Criteria
* Participants with known central nervous system involvement with lymphoma. or diagnosis of primary central nervous system lymphoma (PCNSL) or primary mediastinal large B-cell lymphoma (PMBL).
* Participants with DLBCL had a history of indolent lymphoma such as FL or CLL (Richter's transformation), or was histopathologically comfirmed with FL (regardless of grade) coexistentially.
* Prior treatment with solid organ transplantation or hematopoietic stem cell transplantation(HSCT) ; expected HSCT during the study.
* Major surgery within 4 weeks of study entry or expected major surgery during the study.
* Prior another non-antitumor or medical instruments clinical trials within 4 weeks.
* Known bleeding diseases (such as von Willebrand's disease or hemophilia A, hemophilia B, etc.), or have bleeding tendency.
* Prior treatment with warfarin or equivalent vitamin K antagonists within 14 days; requires anticoagulation with warfarin or equivalent vitamin K antagonists.
* Prior treatment with strong/moderate CYP3A4 inhibitors within 5 days or prior foods with inhibitory effects on CYP3A4 within 3 days at screening; requires chronic treatment with moderate/strong CYP3A inhibitors or inducers, or OATP1B1/OATP1B3 sensitive substrates during the study.
* Participants with other malignancies other than the target indications of this study within the past three years.
* Prior treatment with the cumulative dose of doxorubicin ≥150 mg/m2 (or other anthracyclines at doses converted based on cumulative cardiac toxicity)
* Any serious medical condition including but not limited to uncontrolled hypertension, uncontrolled congestive heart failure or ≥Class 2 cardiac disease as defined by the New York Heart Association Functional Classification or LVEF less than 40%, uncontrolled or symptomatic arrhythmias with corrected QT interval (QTc) \> 480 msec, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, COPD, renal failure, severe hepatic disease, uncontrolled active infection, active hemorrhage.
* Known HIV infection, or syphilis infection, or hepatitis B DNA or hepatitis C RNA positive.
* Known diseases that affect drug swallowing or absorption.
* Unfit to participate in this study in the investigator's opinion.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Lupeng Pharmaceutical Company LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qingqing Cai, Ph D
Role: STUDY_CHAIR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppa S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Duhrsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.
Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LP-168-CN301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.